Drug Profile
304
Alternative Names: 304 - 3SBio; 304R; 304R - 3SBioLatest Information Update: 21 Jun 2021
Price :
$50
*
At a glance
- Originator 3SBio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Non-Hodgkin's lymphoma
Most Recent Events
- 18 Dec 2018 Sunshine Guojian Pharmaceutical initiates enrolment in a phase I trial for Non-Hodgkin lymphoma in China (NCT03980379)
- 01 Mar 2018 304 is awaiting approval for the treatment of Non-Hodgkin lymphoma in China
- 22 Sep 2016 Preregistration for Non-Hodgkin's lymphoma in China (Parenteral) before September 2016 (3SBio pipeline, September 2016)